Application of anisodamine hydrobromide
By regulating key proteins in lung tissue, scopolamine hydrobromide improves microcirculation and organ function in patients with sepsis and septic shock, solving the problem of the lack of effective treatments for septic shock in existing technologies, and significantly improving patient survival and clinical symptoms.
Patent Information
- Application Number
- CN202411235628.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2026-03-10
AI Technical Summary
Current technologies lack a clear mechanism for treating septic shock, especially in improving microcirculation and organ dysfunction. The role and mechanism of scopolamine hydrobromide have not been fully explored.
Scopolamine hydrobromide is used to regulate proteins in lung tissue, including lung tissue plasma membrane microvesicle-associated proteins, energy metabolism-related proteins, matrix metalloproteinases, adhesion junction proteins, and tight junction proteins. It maintains ATP5A levels, inhibits MMP-9 and MMP-2, promotes VE-cadherin expression, reverses the downregulation of JAM-1, maintains Collagen IV and Lamin levels, improves the degradation of Occludin and Claudin-5, protects lung tissue in sepsis patients, improves microvascular permeability and leukocyte adhesion, and regulates vital signs such as blood gas parameters, arterial pressure, and body temperature.
Scopolamine hydrobromide significantly improved lung tissue morphology in patients with sepsis and septic shock, increased survival rate, improved microcirculatory disturbances, reduced Evans blue exudate, inhibited leukocyte adhesion, and increased blood oxygen partial pressure, blood oxygen saturation, and blood pH, thus significantly improving patient survival rate and clinical symptoms.